FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
Patalganga plant received zero observation from USFDA earlier
Health innovations are viewed more positively than food and agricultural technologies
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
The dispute stems from an earlier circular by Zuventus allegedly accusing Zorvia of market sabotage
Subscribe To Our Newsletter & Stay Updated
